Bcl-2 antagonist apogossypol (NSC736630) displays single-agent activity in Bcl-2 transgenic mice and has superior efficacy with less toxicity compared with gossypol (NSC19048)

Blood

Volumn 111, Issue 6, 2008, Pages 3211-3219

  Kitada, Shinichi ^a,b   Kress, Christina L ^a   Krajewska, Maryla ^a   Jia, Lee ^c   Pellecchia, Maurizio ^a   Reed, John C ^a,b  

^a BURNHAM INSTITUTE   (United States)

^b Chronic Lymphocytic Leukemia (CLL) Research Consortium   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOGOSSYPOL; GOSSYPOL; GOSSYPOL DERIVATIVE; PROTEIN BCL 2; UNCLASSIFIED DRUG; DRUG DERIVATIVE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN CELL; LD 50; LIVER TOXICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE; ANIMAL; B CELL LYMPHOMA; B LYMPHOCYTE; BAGG ALBINO MOUSE; CELL CULTURE; CELL SURVIVAL; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; LEUKEMIA; METABOLISM; PATHOLOGY;

ANIMALS; B-LYMPHOCYTES; CELL SURVIVAL; CELLS, CULTURED; FEMALE; GOSSYPOL; HUMANS; LEUKEMIA; LYMPHOMA, B-CELL; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 42449147919     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-09-113647     Document Type: Article

References (29)

1. Campos L. Rouault J-P. Sabido O. et al. High expression of Bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood. 1993;81:3091-3096.
2. Reed JC, MiyashitaT, Krajewski S, et al. Bcl-2 family proteins and the regulation of programmed cell death in leukemia and lymphoma. Cancer Treat Res. 1996;84:31-72.
3. Kornblau SM, Thall PR Estrov Z, et al. The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics. Clin Cancer Res. 1999;5:1758-1766.
4. Reed JC, Kitada S, Takayama S, Miyashita T. Regulation of chemoresistance by the Bcl-2 oncoprotein in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines. Ann Oncol. 1994; 5(suppl 1):S61-S65.
5. Alnemri ES, Fernandas TF, Haldar S, Croce CM, Litwack G. Involvement of Bcl-2 in glucocorticoidinduced apoptosis of human pre-B-leukemias. Cancer Res. 1992:52:491-495.
6. Reed JC. Bcl-2 family proteins: regulators of chemoresistance in cancer. Toxicol Lett. 1995;82-83: 155-158.
7. Reed JC, Stein C, Subasinghe C, et al. Antisense-mediated inhibition of BCL2 proto-oncogene expression and leukemic cell growth and survival: comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides. Cancer Res. 1990;50:6565-6570.
8. O'Brien S, Moore JO, Boyd TE, et al. Randomized phase 3 trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2007;25:1114-1120.
9. Cimmino A, Calin GA. Fabbri M. et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Nat Acad Sci U S A. 2005;102:13944-13949.
10. Calin GA, Croce CM. MicroRNA-signatures in human cancers. Cancer. 2006;6:857-866.
11. Calin GA, Croce CM. MicroRNAs and chromosomal abnormalities in cancer cells. Oncogene. 2006;25:6202-6210.
12. Becattini B, Kitada S, Leone M, et al. Rational design and real time in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-Xl. Chem Biol. 2004;11:389-395.
13. Zhai D, Jin C, Satterthwait AC, Reed JC. Comparison of chemical inhibitors of anti-apoptotic Bcl-2-family proteins. Cell Death Differ. 2006;13: 1419-1421.
14. Bremer T, Man A, Kask K, Diamond C. CACNA1 C polymorphisms are associated with the efficacy of calcium channel blockers in the treatment of hypertension. Pharmacogenomics. 2006;7:271-279.
15. Jia L. Coward LC, Kerstner-Wood C, et al. Comparison of pharmacokinetic and metabolic profiling among gossypol, apogossypol and apogossypol hexaacetate. Cancer Chemother Pharmacol. 2008;61:63-73.
16. Katsumata M, Siegel RM, Louie DC, et al. Differential effects of Bcl-2 on B and T lymphocytes in transgenic mice. Proc Natl Acad Sci U S A. 1992; 89:11376-11380.
17. Faguet GB. Agee JF. Immunophenotypic diagnosis of clinical and preclinical chronic lymphatic leukemia by using monoclonal antibodies against the cCLLa. a CLL-associated antigen. Blood. 1988;72:679-684.
18. Matutes E, Owusu-Ankomah K, Morilla R, et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia. 1994;8:1640-1645.
19. Miller J, Lenz D. Development of an immunoassay for diagnosis of exposure to toxic organophosphorus compounds. J Appl Toxicol. 2001;21: S23-S26.
20. Schimmer AD, Welsh K, Pinilla C, et al. Smallcule antagonists of apoptosis-suppressor XIAP exhibit broad anti-tumor activity. Cancer Cell. 2004;5:25-35.
21. Shami PJ, SaavedraJE, Bonifant CL et al. Antitumor activity of JS-K [02-(2,4-dinitrophenyl)1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1, 2-diolate] and related 02-aryl diazeniumdiolates in vitro and in vivo. J Med Chem. 2006;49: 4356-4366.
22. Coward L, Gorman G, Noker P, et al. Quantitative determination of apogossypol, a pro-apoptotic analog of gossypol, in mouse plasma using LC/MS/MS. J Pharm Biomed Anal. 2006;42: 581-586.
23. Zapata JM, Krajewska M, Morse HC III, Choi Y, Reed JC. TNF receptor-associated factor (TRAF) domain and Bcl-2 cooperate to induce small B cell lymphoma/chronic lymphocytic leukemia in transgenic mice. Proc Nat Acad Sci U S A. 2004; 101:16600-16605.
24. Zapata JM, Krajewska M, Krajewski S, et al. TRAF-family protein expression in normal tissues and lymphoid malignancies. J Immunol. 2000; 165:5084-5096.
25. Pierce GF, Polmar SH. Lymphocyte dysfunction in cartilage-hair hypoplasia: evidence for an intrinsic defect in cellular proliferation. J Immunol. 1982;129:570-575.
26. Cory S, Huang DC, Adams JM. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene. 2003;22:8590-8607.
27. Konopleva M, Contractor R, Tsao T, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell. 2006;10: 375-388.
28. Hochman A, Sternin H, Gorodin S, et al. Enhanced oxidative stress and altered antioxidants in brains of Bcl-2-deficient mice. J Neurochem. 1998;71:741-748.
29. Lee HH, Dadgostar H. Cheng O, Shu J, Cheng G. NF-kB-mediated up-regulation of bcl-x and bfl-1/a1 is required for CD40 survival signaling in B lymphocytes. Proc Natl Acad Sci U S A. 1999;96: 9136-9141.